TABLE 3.
Antimicrobial susceptibility profile of all 30 MRSE isolates (76.6% MDR) included in this studya
| Antimicrobial agent | MIC (μg/ml) |
Susceptibility profile (%)b |
||||
|---|---|---|---|---|---|---|
| Range | MIC50 | MIC90 | S | I | R | |
| Ciprofloxacin | 0.5 to >16 | >16 | >16 | 23.3 | - | 76.7 |
| Ofloxacin | 0.25 to >16 | 8 | 16 | 26.7 | - | 73.3 |
| Moxifloxacin | ≤0.12 to >16 | 1 | 2 | 36.7 | 30.0 | 33.3 |
| Azithromycin | 0.5 to >32 | >32 | >32 | 36.7 | - | 63.3 |
| Tobramycin | ≤0.25 to >32 | 4 | 16 | 50.0 | 29.9 | 20.1 |
| Gentamicin | ≤0.25 to >32 | 16 | >32 | 43.3 | 3.4 | 53.3 |
| Clindamycin | ≤0.12 to >16 | ≤0.12 | >32 | 70.0 | 3.4 | 26.6 |
| Chloramphenicol | 2 to 64 | 4 | 64 | 73.3 | - | 26.7 |
| Trimethoprim-sulfamethoxazole | ≤0.25 to >32 | ≤0.25 | 4 | 86.2 | - | 13.8 |
| Linezolid | 0.5 to 2 | 1 | 2 | 100 | - | - |
| Vancomycin | ≤0.5 to 2 | 2 | 2 | 100 | - | - |
a
Multidrug-resistant (MDR) isolates are defined as isolates resistant to at least three antimicrobial classes.
b
Interpretive criteria as published by Clinical and Laboratory Standards Institute in 2013 (M100-S23): S, susceptible; I, intermediate; and R, resistant.